For immediate release

Press Release

IOL Chemicals and Pharmaceuticals Limited going to launch API business to US Market

Ludhiana, 20 July 2015 – IOL Chemicals and Pharmaceuticals Limited (IOLCP), producers of APIs has announced that the company has received from US Food and Drug Administration (USFDA), Establishment Inspection Report after successful inspection of its Ibuprofen manufacturing facility situated at Barnala, Punjab, India.

Post this approval, IOLCP will be able to garner additional business for its flagship API lbuprofen in World's largest pharma market-USA. This will result into higher value added export turnover and higher margins.

The Company's manufacturing facility already hold CEP certification (Certificate of Suitability) for its products Ibuprofen, Metformin Hydrochloride & Lamotrigine from European Directorate for the Quality of Medicines & HealthCare (EDQM) authorities, Council of Europe, France. The said facility at Barnala has also been approved by ANVISA Brazil, WHO & MOH Japan.

These approvals will help IOLCP to build and sustaining the growth by its API business in coming years, being the only integrated player globally, by exploring the higher value added regulated markets.

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986, listed on Bombay Stock Exchange (Code: 524164) and the National Stock Exchange (Code: IOLCP) is India's one of the leading generic pharmaceutical companies, and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, Anti-diabetic, Anti hypertensive, Anti Convulsants, etc.

IOLCP's product portfolio includes APIs; Ibuprofen, specialty chemicals such as Iso Butyl Benzene (IBB), Ethyl acetate, Mono Chloro Acetic Acid and Acetyl Chloride.

Company is world's only largest backward integrated Ibuprofen producer with an installed capacity of 6000TPA, manufacturing all intermediates stages and Key Starting Materials at one location. The company has DSIR approved R&D which is fully equipped to validate existing processes. State of art Multipurpose plant provides significant upside opportunity for further development of APIs.

Head Office: 85, Industrial Area 'A', Ludhiana, 141 003 (Pb.) India—CIN - L21116PB1986PLC007030 Ph.: +91-161-2225531-35 Fax: +91-161-2226929, 2608784 email: contact@iolep.com Website: iolep.com

Regd. Office: Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India

Works: Trident Complex, Mansa Road, Vill Fatehgarh Channa, Barnala-148101. (Pb.) India

Ph.: +91-1679 -285285-86. Fax: +91-1679-285292

The Central and State Government approved Effluent Treatment Plant (ETP) was set up with zero effluent discharge system alongwith 17 MW captive Co-Generation plant for self reliance.

IOLCP's overseas customers are spread out across several countries including Brazil, Argentina, China, Hungry, USA, Chile, Peru, Colombia, South Africa, Thailand, Australia, Israel, Netherlands, Iran and many other Middle East Countries. Products are sold primarily to Branded Generic formulators both in India & Overseas.

The company is continuous winner of National Energy Conservation award for last 10 years and also recently awarded with National Award for Technology Innovation 2014-15. Company is an - ISO 9001:2008, ISO 14001:2004 and OHSAS 18001:2007

For more information on IOLCP, please visit http://www.iolcp.com